Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Lung Cancer Update
00:00
EJFR-X-on-20 Infections - What's the Difference?
In which line of treatment do you administer targeted therapy to your patients with metastatic non-small cell lung cancer with EJFR-X-on-20 insertions? And how do you select between the available therapies? The answer is ami-vantimab and mobo-certainib. But they also have differences as far as the toxicity profile. Diarrhea in 90% of patients, one in five, it's a grade three diarrhea. We also see Paranicky and some cardiac toxicities.
Transcript
Play full episode
